Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Enters 2021 with Optimism for Its Cancer Imaging Technology

• Imagin Medical Inc. successfully weathered the 2020 pandemic-induced economic challenges and transitioned its surgical visualization product, the i/Blue Imaging System(TM) from the development stage to manufacturing  and has  after
• Imagin’s next stage will be supported by a $3 million convertible note, with the final funding tranche expected to close this quarter
• The i/Blue Imaging System combines the advantages of blue light with advanced optic and light sensors to address the limitations of both white and blue light imaging to help surgeons better visualize and remove cancerous cells. The system uses a contrast agent to highlight the cancer and projects both the white and blue light images side-by-side simultaneously on the surgical monitor
• Bladder cancer is the sixth most prevalent cancer in the U.S., the third most common cancer in men, more than 17,000 deaths are expected in the U.S. this year due to bladder cancer
• Once Imagin obtains final FDA approval and finishes rolling out its product, the company expects to expand its product line by adapting its IP for use with multiple contrast agents for use in other minimally invasive surgeries

Following an unusual series of hardships for North America, as well as the world at large, during the past year, people are beginning to see reasons for optimism that 2021 will deliver better economic news, less political unrest and an overall reversal of the COVID pandemic’s persistently climbing death and disability toll.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), has achieved significant milestones during 2020 despite the obstacles posed by COVID and other adverse factors. Imagin’s strategy has positioned the company for greater strides in the coming year as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.